Formulations for children: problems and solutions - Wikidata - awgldk - TriplyDB

Formulations for children: problems and solutions

Formulations for children: problems and solutions

http://www.wikidata.org/entity/Q35135943

about

Systemic side effects of eye drops: a pharmacokinetic perspective Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.Paediatric prescribing: why children are not small adults.Pediatric ocular nanomedicines: Challenges and opportunities.Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status.Prolonged-release minitablets with carbamazepine - preliminary observations in vitro.

P2860

Q28066720-322433A9-AF71-41D2-BE8B-0AC00A4B5877 Q38375177-5B4CFAC2-FD3F-4630-B813-CC7DC5658824 Q38545613-54BE4F0A-47AE-4D7B-A021-25445A674252 Q38819654-22DB3824-28BD-4AF8-9831-72771E0EC150 Q42586100-A1A23B1F-8320-4F58-80D9-C0A140D96CDD Q45073189-755C217C-AA79-4E51-924F-85BEE9DEEEE4 Q47781069-82124167-3815-44F9-92D7-9BE49A9264D5 Q50861442-00814453-7F02-460F-B762-6F51D517EE73

P2860

Formulations for children: problems and solutions

http://www.wikidata.org/entity/Q35135943

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Formulations for children: problems and solutions

@ast

Formulations for children: problems and solutions

@en

type

label

Formulations for children: problems and solutions

@ast

Formulations for children: problems and solutions

@en

prefLabel

Formulations for children: problems and solutions

@ast

Formulations for children: problems and solutions

@en

P1433

Q35135943-393D8D29-14A7-49DB-BDC1-A00B9B44B63C

P1476

Q35135943-08D8FE62-B92F-41B4-A162-501B6E5CE503

P2093

Q35135943-43E9915F-F012-4F07-B501-607DBC1F012E

P2860

Q35135943-020250A6-0F29-4BAB-9814-15CD04532429

Q35135943-08314219-C1BB-4D7C-96B9-63B8091D9702

Q35135943-0A92CEB7-1D69-4EAE-89D9-A62BF6E14DC4

Q35135943-0AD34175-9DAE-44E6-AF89-4DF79D42F4D0

Q35135943-0F5DE92A-7A2F-486A-B2B0-B936DD8C6011

Q35135943-10A3C2C1-3F6F-4288-98EE-DE67792496EB

Q35135943-13654818-C654-457D-BE58-ADC347732F60

Q35135943-16EE51E9-C778-4A4F-8480-66A61C2FA68E

Q35135943-1B55DC09-8675-47F7-860A-1386F040CECE

Q35135943-231E14BB-36E4-45E3-8866-73A15C43DE29

P304

Q35135943-FBD4835C-5B88-4CB3-B018-B6A781E6BF6F

P31

Q35135943-1A367F83-D3AB-41AC-9532-AE39C3A5A1DF

P356

Q35135943-15EA9948-FC48-4784-8184-CED81A9DE1FA

P407

Q35135943-E9817550-50AD-4495-9F10-1951C6F9F842

P433

Q35135943-24EB1865-A171-46FD-97DF-2BE0F5151BA9

P478

Q35135943-5D8610A6-BE0E-4964-9E3B-C8D63A3A0A2B

P50

Q35135943-8C33199D-45D2-4566-B44E-F1A5E5BCF0DF

P577

Q35135943-285FE863-3DBB-4AA1-B90A-B44AF38D675E

P698

Q35135943-453C79D5-36EE-43ED-8472-10BB2F2AD65D

P932

Q35135943-133D1879-8821-421C-8F29-A2B590304D74

P356

P1433

British Journal of Clinical Pharmacology

P1476

Formulations for children: problems and solutions

@en

P2093

John F Marriott

http://www.w3.org/2001/XMLSchema#string

P2860

Ophthalmic drops causing coma in an infant.

Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.

Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study.

The economics of pediatric formulation development for off-patent drugs.

A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study

Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation.

Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast.

Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects

P304

405-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12268

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Hannah Batchelor

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25855822

http://www.w3.org/2001/XMLSchema#string

P932

4345951

http://www.w3.org/2001/XMLSchema#string